Merck & Co. has agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion, in a deal designed to bolster the buyer’s cancer pipeline with that of Terns—led by an oral tyrosine kinase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results